About
Small molecule for Wilson's disease
Areas of Focus
Categories
Small Molecule Pharmaceutical
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
5
As Collaborator
0
Total Enrollment
663
By Phase
PHASE2: 1PHASE1: 1PHASE3: 1
By Status
RECRUITING: 2COMPLETED: 2ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT07010575Lead Sponsor
Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride
PHASE2Recruiting
10 participants
Started: Jul 15, 2025 · Completed: Dec 31, 2025
NCT06128954Lead Sponsor
Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily).
PHASE1Completed
26 participants
Started: Jan 16, 2024 · Completed: Feb 16, 2024
NCT05783687Lead Sponsor
Real World Evidence Study in Subjects With Wilson's Disease
N/AActive, not recruiting
50 participants
Started: Jun 28, 2023 · Completed: Dec 31, 2025
NCT05239858Lead Sponsor
International Wilson's Disease Patient Registry (iWilson Registry)
N/ARecruiting
500 participants
Started: Jun 29, 2022 · Completed: Dec 31, 2027
NCT03539952Lead Sponsor
Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease
PHASE3Completed
77 participants
Started: Sep 3, 2018 · Completed: Jan 18, 2022
Locations (1)
Headquarters
Paris, France
Map
Loading map...